Purpose: Super-refractory status epilepticus (SRSE) represents a challenging medical condition with high morbidity and mortality. In this study, we aimed to establish variables related to SRSE development and outcome. Methods: We retrospectively screened our databases for refractory SE (RSE) and SRSE episodes between January 2001 and January 2015. Baseline demographics, SE characteristics, and variables reflecting the clinical course were compared in order to identify factors independently associated with SRSE occurrence. Within the SRSE cohort, predictors of in-hospital mortality as well as good functional outcome in survivors to discharge were established through univariate and multivariable analyses. Results: A total of 131 episodes were included, among those 46 (35.1%) meeting the criteria of SRSE.
Introduction
Up to 40% of status epilepticus (SE) episodes do not respond to first-and second-line therapy (=refractory SE, RSE) and may require therapeutic coma with continuous infusion of anesthetics for seizure control [1] . Seizures can persist despite induction of coma, however, and in 10-15% of all SE episodes they do so after more than 24 h of continuous anesthetic therapy, or recur on reduction or withdrawal of anesthetics. The resulting condition, according to a recent definition [2] , was coined super-refractory SE (SRSE). Although there are studies on comparable entities like prolonged RSE (PRSE) or malignant SE (MSE) (both meeting the criteria of SRSE), the overall available data on this extreme variant of SE is limited [3, 4] .
On the one hand, the mechanisms involved in the transition from RSE to SRSE are poorly understood [5] . On the other hand, data on mortality and functional outcome vary significantly and have been reported to be ranging from death to even good functional recovery [4, 6] . Given this prognostic uncertainty, therapeutic decision making in SRSE is challenging, especially in extremely long episodes in which the question of how long to maintain therapy may ultimately be raised [6] . Therefore, the primary goal of this study was to assess predictors of SRSE Abbreviations: AED, antiepileptic drug; CI, confidence interval; EEG, electroencephalography; IQR, interquartile range; RSE, refractory status epilepticus; SE, status epilepticus; SRSE, super-refractory status epilepticus; STESS, Status Epilepticus Severity Score; mRS, modified Rankin Scale; NCSE, nonconvulsive status epilepticus.development. A secondary objective was to establish factors influencing outcome in a large cohort of SRSE episodes.
Methods

Definition of super-refractory status epilepticus
We applied the definitions commonly used in the current literature and defined status epilepticus as seizures persisting for at least 5 min or as a series of seizures without interictal clinical recovery [7] . SE intractable to adequate first-and second-line therapy was defined as refractory SE (RSE) [8] . RSE with persisting seizures despite administration of anesthetics for at least 24 h was defined as SRSE. So were RSE episodes in which seizures recurred during tapering or after discontinuation of anesthesia if patients did not show clear signs of intermittent clinical recovery [2] .
Study population
The medical files of all cases treated for SE in our institution from January 2001 until January 2015 were reviewed and screened for episodes meeting the above mentioned criteria for RSE and SRSE. We excluded (S)RSE secondary to hypoxic brain damage as well as episodes in which seizures were not terminated and patients were not treated with therapeutic coma, as these might have turned out super-refractory if anesthetics had been given. Per definition, all SRSE episodes are also RSE episodes; in this study, for the purpose of statistical comparison, however, the RSE cohort consisted exclusively of RSE episodes which did not progress into SRSE. The study was approved by the Local Ethics Committee of the Friedrich-Alexander University Erlangen-Nürnberg, Germany (vote number: 48_15Bc).
Clinical data
Data were extracted from our files, EEG database, and medical records systems separately by two investigators (DM and RUK) using a standardized data collection form. In case of disagreement, consensus was found through discussion including a third investigator (HBH). Demographic data collected were age at admission, gender, and premorbid functional status. The following (S)RSE characteristics were gathered: mental status at presentation, worst seizure type before treatment, etiology, and duration of seizures. The latter was defined as time between the onset of seizures until their definite and enduring electroencephalographic and/or clinical termination. (S)RSE etiologies were adopted from the discharge summaries and were 1) categorized according to ILAE definitions (acute, remote, progressive symptomatic, or unknown etiology) [9] and 2) dichotomized into inflammatory and noninflammatory (based on the interpretation of clinical and laboratory/CSF findings documented in the records). We also identified episodes with a potentially fatal etiology according to the criteria proposed by Rossetti et al. as well as those in which patients had a known history of seizures [10] . We calculated the Status Epilepticus Severity Score (STESS) for every episode. A STESS of 3 or more points was considered unfavorable and episodes were dichotomized accordingly [11] . Regarding treatment and complications during the hospital stay, we extracted information on the overall duration of hospital stay, the duration of mechanical ventilation, the induction of burst-suppression, the occurrence of sepsis, the need for application of vasopressors, and the total number of antiepileptic drugs (AEDs) applied. Initial benzodiazepines as well as anesthetics were defined as AEDs and thus contributed to the overall number of AEDs given. If a patient suffered more than one (S)RSE episode during the study period, only the first one was included into the study.
Outcome definition
Functional outcome was measured by the modified Rankin Scale score (mRS) at time of hospital discharge [12] . In the SRSE subgroup, an additional outcome after discharge was assessed using last available follow-up information from our records. If patients were readmitted because of another SE episode, the mRS prior to the onset of this second episode was defined as follow-up outcome of the first episode. We compared the premorbid mRS with the mRS at discharge and defined complete recovery during hospital stay as when these scores did not differ. Patients discharged home or to palliative care with ongoing seizures, or in an overall very bad clinical condition indicating imminent death, were defined as having died in hospital. Good outcome was defined as either a return to premorbid functional baseline or as a final mRS of 2.
Statistical analysis
We used SPSS 20.0 (http://www.spss.com) for all statistical calculations. Proportions were compared using Pearson's x
or
Fisher's exact test where appropriate. Continuous variables were compared using the Mann-Whitney U test. All tests were twosided and p-values of <0.05 were considered statistically significant. Variables showing significant differences or a statistical trend (p < 0.075) in the univariate comparison between groups were considered candidate covariates for multivariable analysis using binary logistic regression with forced entry of variables. A total of three multivariable models were created to identify factors independently associated with progression into SRSE, in-hospital mortality in the SRSE cohort, and functional outcome at last available follow-up in SRSE survivors to discharge. Age, as a factor previously associated with both occurrence and outcome of SRSE [5, 11] , was included in the models regardless of the results of univariate analyses. Covariates were tested for multicollinearity using the variance inflation factor (VIF) with a cutoff of 3.
Results
Study population
A total 569 SE episodes were identified during the study period, of which 159 (27.9%) satisfied the criteria of RSE. Among those were 14 recurrent RSE episodes which were excluded from further analysis.
So were 14 more episodes in which patients were not treated with anesthetics although seizures were intractable to nonanesthetic AEDs, leaving 131 episodes for final analysis, of which 46 (35.1%) were SRSE (Table 1a) . Median age in the overall cohort was 70 years (IQR, 56-77), and median premorbid mRS was 3 (IQR, 1-4). The median seizure duration in all episodes was 7 (IQR, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] days and patients were treated in hospital for 18 (IQR, 10-31) days. The median number of AEDs needed for seizure control was 5 (IQR, 4-7), in 75 (57.3%) episodes patients were treated with anesthetics with burst suppression induced in 53 (40.5%) of all cases.
Predictors of progression of RSE into SRSE
Regarding baseline demographics, a lower premorbid mRS score was significantly associated with SRSE (Table 1a) and turned out an independent risk factor upon multivariable analysis (OR, 0.769; p = 0.039; Table 1b ). In terms of seizure characteristics, NCSE in coma as worst seizure type was the only factor independently associated with SRSE (OR, 4.216; p = 0.008). STESS was similar in both groups with an unfavorable score of 3 in a comparable number of episodes. RSE caused by inflammation tended to be more likely to progress into SRSE; however, after adjustment for premorbid functional status, age, and NCSE in coma this trend was lost (OR, 2.028; p = 0.155).
Clinical course and complications
With regards to clinical course and complications, SRSE and RSE cases differed highly significantly in every aspect studied (Table 1a) : SRSE episodes were longer (21 vs 4d; p < 0.001), resulted in longer overall hospital stays (38 vs 14d; p < 0.001), were treated with more AEDs (8 vs 4; p < 0.001), had burst suppression induced more frequently (93.5 vs 11.8%; p < 0.001), led to more frequent use of vasopressors (93.5 vs 29.4%; p < 0.001), and were more likely to be complicated by sepsis (41.3 vs 17.6%; p = 0.003).
Overall outcome at discharge
Outcome was worse in the SRSE cohort with significantly more deaths during hospital stay (30.4 vs 14.1%; p = 0.025; Table 1a ) and overall higher mRS scores at discharge, despite identical medians (5 vs 5; p < 0.001). Recovery to premorbid baseline prior to discharge occurred significantly rarer (6.5 vs 38.8%; p < 0.001) among SRSE patients.
Factors associated with in-hospital mortality in the SRSE cohort
Patients who died in hospital were significantly older (76 vs 65y; p = 0.006), tended to have a worse premorbid functional status (3 vs 1 mRS point; p = 0.034), and were diagnosed with sepsis more frequently (64.3 vs 31.2%; p = 0.036; Table 2a ). Gender was not associated with in-hospital mortality. Duration of SRSE was similar in both cohorts (16 vs 23d; p = 0.256), whereas the length of hospital stay was significantly shorter (23 vs 40d; p = 0.013) and the number of applied AEDs significantly lower in nonsurvivors (6 vs 9; p = 0.001). Upon multivariable analysis, only age (OR, 1.091; p = 0.020) and premorbid functional status (OR, 1.938; p = 0.044) turned out independent predictors of in-hospital mortality (Table 2b) ; for reasons of multicollinearity, the number of AEDs applied was not entered into the regression model. 3.6. Factors associated with good outcome at last available follow-up in SRSE survivors to discharge
Median time between discharge and follow-up was 12 weeks (IQR, 7-20; range, 125). Good outcome at last available follow-up was strongly associated with shorter SRSE duration (12 vs 31d; p < 0.001), however not with gender or patient age (Table 3a) . Other related factors were shorter time on the ventilator (14 vs 33d; p = 0.001) and overall lower number of AEDs needed for seizure control (8 vs 10; p = 0.006). Because of multicollinearity, these two variables were removed from the logistic regression model which revealed shorter SRSE duration to be an independent predictor of SRSE (OR, 0.714; p = 0.038; Table 3b ).
Discussion
The aim of this study was to identify predictors of progression of RSE into SRSE and to establish variables associated with outcome. Key findings were that (i) SRSE occurrence was related to better premorbid functional status and NCSE in coma as worst seizure type, (ii) in-hospital mortality was determined by age and premorbid functional status, and (iii) functional outcome in survivors was significantly influenced by seizure duration. Several aspects deserve attention.
First, what are the mechanisms underlying the association between good premorbid functional status and SRSE occurrence? A plausible explanation could include differences in causative SE etiologies, as patients in reduced functional status prior to SE are likely to have preexisting brain damage accounting for their impairment, and SE arising from such static brain injury (i.e., remote symptomatic SE) was shown to have low risk of being refractory to treatment [5] . In functionally intact individuals without history of previous seizures or idiopathic epilepsy, on the other hand, SE frequently results from some form of acute brain insult (e.g., cerebrovascular accidents or CNS infections) [13] which has been linked to refractoriness to therapy in SE [14] . Our finding that NCSE in coma independently predicted SRSE in our cohort supports this hypothesis, as NCSE in coma is known to frequently result from severe (i.e., typically acute) underlying pathologies [15] [16] [17] . Given these considerations, one would expect to (a) observe significant differences between RSE and SRSE regarding underlying etiologies categorized according to ILAE recommendations and to (b) find a history of previous seizures to be rarer in the SRSE cohort. However, this is not the case, which indicates that, while acute underlying pathologies may represent one aspect in SRSE development, the overall mechanisms involved appear to be far more complex [5] , including molecular and cellular processes of which many still are only partly understood [18] [19] [20] [21] .
The literature on prediction of SRSE occurrence is scarce and differences in study settings and definitions applied limit the number of previous research our results can be compared with. In line with our findings, a recent study on a large prospectively collected cohort of (S)RSE episodes from Switzerland reported no differences in underlying etiologies according to ILAE between SRSE and RSE, and also found NCSE in coma to be more common in Abbreviations: AED = antiepileptic drug; mRS = modified Rankin Scale; NCSE = nonconvulsive status epilepticus; RSE = refractory status epilepticus; SE = status epilepticus; STESS = Status Epilepticus Severity Score; Values are n (%) or median (interquartile range); significant (p < 0.05) parameters are expressed in bold. SRSE [5] . Freedom from relevant comorbidities was more frequent in their SRSE cohort, which might indirectly point toward a lower degree of preexisting disability as compared to RSE and thus further corroborate our findings [22] . Second, regarding outcome, we observed that variables generally associated with poor prognosis in SE like longer duration of seizures, the occurrence of sepsis, and the use of vasopressors were more common in SRSE than RSE [23] [24] [25] . It is therefore not surprising that overall outcome was significantly worse after SRSE, and our results here compare very well with previous studies [26] . Within the SRSE cohort, death during hospital stay was only predicted by older age and worse premorbid functional status. This association may be explained by the fact that in-hospital mortality in SRSE is known to be primarily driven by complications of intensive care treatment and/or withdrawal of therapy [6, 27] , which are both more likely to occur in older patients in reduced premorbid condition.
Third, in order to assess determinants of functional recovery after SRSE, we performed an a priori defined subgroup analysis of SRSE survivors to discharge, which revealed a clear impact of seizure duration on outcome at last available follow-up. The role of seizure duration in outcome after SE is controversial [26] . Results of several studies point toward a loss of its predictive significance already a few hours into an SE episode, calling into question its relevance for functional outcome in a condition like SRSE, where seizures typically persist for days or weeks [28, 29] . Accordingly, and in contrast to our results, Lai et al. found seizure duration not to differ between patients with good and poor outcome after SRSE [6] . However, poor outcome in their study included death during hospital stay. The decision to withdraw supportive care can lead to shorter SE durations in nonsurvivors as compared to survivors [27] , which might contribute to the discrepancy between their results and ours.
Our study has several clear limitations, including the singlecenter retrospective design. Moreover, the recruitment period was very long and changes in SE definitions, treatment protocols, and technical equipment resulted in an inhomogeneous study cohort. To account for varying SE definitions over time, we applied a wide range of search terms in the query of our databases and thoroughly reviewed the paper charts whenever there was doubt about the diagnosis. Still, the distribution of (S)RSE episodes was markedly uneven with only a relatively small number of cases from before 2008. However, rather than pointing toward invalidity of our case identification algorithm, this is more likely caused by a shift in our department's medical focus to acute neurocritical care in 2007 as well as the fact that around that time new AEDs in intravenous formulation became available. Their use was found to be associated with increasing RSE rates in recent research from Switzerland, probably due to a favorable risk-benefit profile leading clinicians to apply them early in the course of SE treatment, potentially before an earlier stage AED had enough time to act [30] . Given these considerations, the definition of RSE as failure of two AEDs to terminate SE without an additional time criterion appears problematic. It is, however, widely accepted and applied in the literature, which is why we adopted it in the present study. The definition of SRSE is based on treatment with anesthetics; therefore, we excluded patients who did not receive anesthetics despite failure of non-anesthetic AEDs to abort the RSE. Although this approach gives rise to the risk of selection bias, we consider not including these patients in the RSE cohort justified, as they were significantly older, in worse premorbid condition, and tended to receive fewer AEDs than the included episodes despite comparable RSE durations (Supplemental Table 1 ). Therefore, the deviation from SE treatment protocol with lacking escalation to anesthetics in these patients most likely reflected limitation of therapy.
Given the shortage of data on factors contributing to SRSE development and outcome, we primarily used univariate analysis to define candidate variables for the multivariable models, and, with the exception of age, not covariates defined in advance based on clinical considerations. Although we assessed numerous clinical variables, the associations we observed in these models may be confounded by factors not analyzed in our study.
Outcome after discharge was not assessed at defined time points and we had to rely on information available in our records. Of note, in the majority of our patients, time to follow-up was within a range allowing for reasonable assessment of longer-term outcome after SRSE.
Regarding outcome categorization, in case of final mRS scores >2 episodes were still defined to have resulted in good outcome when SE did not lead to increase in the mRS. This approach introduces some risk of erroneously categorizing patients to have good outcome especially in those with severe preexisting disability, as mRS may be too imprecise a tool to adequately reflect additional injury caused by SRSE in these individuals. Still, given relevant disability prior to SE in many patients, this approach seems more appropriate for our cohort than using an mRS cutoff exclusively.
Conclusions
Our findings link SRSE development to acute etiologies, but also indicate that additional parameters beyond those assessed in this study are involved. While in-hospital mortality is particularly determined by age and premorbid functional status and not seizure activity per se, functional outcome in survivors is influenced by the duration of SRSE, underscoring the need for rapid seizure termination. Numerous reports of patients who achieved good functional recovery after SRSE despite lack of these favorable outcome predictors, however, clearly demonstrate that therapeutic decisions in SRSE may not be chiefly guided by such factors [4, 26, 31] .
